Review article

Hepatitis C virus and calcineurin inhibition after renal transplantation

F. Fabrizi, J. Bromberg, A. Elli, V. Dixit, Paul Martin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The impact of hepatitis C virus on patient and graft survival after renal transplantation remains controversial. However, recent studies have given emphasis on the detrimental role of hepatitis C on long-term patient and graft survival after renal transplantation. Various mechanisms can promote the lower survival in hepatitis C virus-positive recipients, i.e. post-transplant diabetes mellitus. liver disease and infections. Novel evidence has been accumulated showing the inhibitory activity of ciclosporin on the hepatitis C virus replication rate in human hepatocytes; ciclosporin has been shown in vitro to suppress hepatitis C virus replication as effectively as interferon alpha. This effect has not been seen with tacrolimus and is separate from its immunosuppressive activity. Data from patients with normal kidney function or after bone marrow transplantation show that ciclosporin inhibits hepatitis C virus replication. It appears that the progression of liver fibrosis is slower in hepatitis C virus-positive liver transplant recipients treated with ciclosporin than tacrolimus. In contrast, the clinical outcome of hepatitis C in hepatitis C virus-positive patients after liver transplantation treated with ciclosporin vs. tacrolimus has given mixed results. No information after renal transplantation is available. Various parameters can promote the worsening of hepatitis C after renal transplantation but choice of calcineurin inhibition is one of the few risk factors that can potentially be modified by the physician. Prospective, comparative trials of ciclosporin and tacrolimus with large size and adequate follow-up after renal transplantation are in progress.

Original languageEnglish
Pages (from-to)657-666
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume22
Issue number8
DOIs
StatePublished - Oct 15 2005
Externally publishedYes

Fingerprint

Calcineurin
Hepacivirus
Kidney Transplantation
Cyclosporine
Tacrolimus
Hepatitis C
Virus Replication
Graft Survival
Immunosuppressive Agents
Bone Marrow Transplantation
Interferon-alpha
Liver Cirrhosis
Liver Transplantation
Liver Diseases
Hepatocytes
Diabetes Mellitus
Physicians
Transplants
Kidney
Survival

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Review article : Hepatitis C virus and calcineurin inhibition after renal transplantation. / Fabrizi, F.; Bromberg, J.; Elli, A.; Dixit, V.; Martin, Paul.

In: Alimentary Pharmacology and Therapeutics, Vol. 22, No. 8, 15.10.2005, p. 657-666.

Research output: Contribution to journalArticle

Fabrizi, F. ; Bromberg, J. ; Elli, A. ; Dixit, V. ; Martin, Paul. / Review article : Hepatitis C virus and calcineurin inhibition after renal transplantation. In: Alimentary Pharmacology and Therapeutics. 2005 ; Vol. 22, No. 8. pp. 657-666.
@article{7e369922736a4297839100891ccd4ff4,
title = "Review article: Hepatitis C virus and calcineurin inhibition after renal transplantation",
abstract = "The impact of hepatitis C virus on patient and graft survival after renal transplantation remains controversial. However, recent studies have given emphasis on the detrimental role of hepatitis C on long-term patient and graft survival after renal transplantation. Various mechanisms can promote the lower survival in hepatitis C virus-positive recipients, i.e. post-transplant diabetes mellitus. liver disease and infections. Novel evidence has been accumulated showing the inhibitory activity of ciclosporin on the hepatitis C virus replication rate in human hepatocytes; ciclosporin has been shown in vitro to suppress hepatitis C virus replication as effectively as interferon alpha. This effect has not been seen with tacrolimus and is separate from its immunosuppressive activity. Data from patients with normal kidney function or after bone marrow transplantation show that ciclosporin inhibits hepatitis C virus replication. It appears that the progression of liver fibrosis is slower in hepatitis C virus-positive liver transplant recipients treated with ciclosporin than tacrolimus. In contrast, the clinical outcome of hepatitis C in hepatitis C virus-positive patients after liver transplantation treated with ciclosporin vs. tacrolimus has given mixed results. No information after renal transplantation is available. Various parameters can promote the worsening of hepatitis C after renal transplantation but choice of calcineurin inhibition is one of the few risk factors that can potentially be modified by the physician. Prospective, comparative trials of ciclosporin and tacrolimus with large size and adequate follow-up after renal transplantation are in progress.",
author = "F. Fabrizi and J. Bromberg and A. Elli and V. Dixit and Paul Martin",
year = "2005",
month = "10",
day = "15",
doi = "10.1111/j.1365-2036.2005.02662.x",
language = "English",
volume = "22",
pages = "657--666",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Review article

T2 - Hepatitis C virus and calcineurin inhibition after renal transplantation

AU - Fabrizi, F.

AU - Bromberg, J.

AU - Elli, A.

AU - Dixit, V.

AU - Martin, Paul

PY - 2005/10/15

Y1 - 2005/10/15

N2 - The impact of hepatitis C virus on patient and graft survival after renal transplantation remains controversial. However, recent studies have given emphasis on the detrimental role of hepatitis C on long-term patient and graft survival after renal transplantation. Various mechanisms can promote the lower survival in hepatitis C virus-positive recipients, i.e. post-transplant diabetes mellitus. liver disease and infections. Novel evidence has been accumulated showing the inhibitory activity of ciclosporin on the hepatitis C virus replication rate in human hepatocytes; ciclosporin has been shown in vitro to suppress hepatitis C virus replication as effectively as interferon alpha. This effect has not been seen with tacrolimus and is separate from its immunosuppressive activity. Data from patients with normal kidney function or after bone marrow transplantation show that ciclosporin inhibits hepatitis C virus replication. It appears that the progression of liver fibrosis is slower in hepatitis C virus-positive liver transplant recipients treated with ciclosporin than tacrolimus. In contrast, the clinical outcome of hepatitis C in hepatitis C virus-positive patients after liver transplantation treated with ciclosporin vs. tacrolimus has given mixed results. No information after renal transplantation is available. Various parameters can promote the worsening of hepatitis C after renal transplantation but choice of calcineurin inhibition is one of the few risk factors that can potentially be modified by the physician. Prospective, comparative trials of ciclosporin and tacrolimus with large size and adequate follow-up after renal transplantation are in progress.

AB - The impact of hepatitis C virus on patient and graft survival after renal transplantation remains controversial. However, recent studies have given emphasis on the detrimental role of hepatitis C on long-term patient and graft survival after renal transplantation. Various mechanisms can promote the lower survival in hepatitis C virus-positive recipients, i.e. post-transplant diabetes mellitus. liver disease and infections. Novel evidence has been accumulated showing the inhibitory activity of ciclosporin on the hepatitis C virus replication rate in human hepatocytes; ciclosporin has been shown in vitro to suppress hepatitis C virus replication as effectively as interferon alpha. This effect has not been seen with tacrolimus and is separate from its immunosuppressive activity. Data from patients with normal kidney function or after bone marrow transplantation show that ciclosporin inhibits hepatitis C virus replication. It appears that the progression of liver fibrosis is slower in hepatitis C virus-positive liver transplant recipients treated with ciclosporin than tacrolimus. In contrast, the clinical outcome of hepatitis C in hepatitis C virus-positive patients after liver transplantation treated with ciclosporin vs. tacrolimus has given mixed results. No information after renal transplantation is available. Various parameters can promote the worsening of hepatitis C after renal transplantation but choice of calcineurin inhibition is one of the few risk factors that can potentially be modified by the physician. Prospective, comparative trials of ciclosporin and tacrolimus with large size and adequate follow-up after renal transplantation are in progress.

UR - http://www.scopus.com/inward/record.url?scp=26944452031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944452031&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2005.02662.x

DO - 10.1111/j.1365-2036.2005.02662.x

M3 - Article

VL - 22

SP - 657

EP - 666

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 8

ER -